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Abstract
Untargeted and uncontrolled gene delivery is a major cause of gene therapy failure. This study aimed to define efficient and
safe tissue-selective targeted gene therapy approaches for delivering genes into keratocytes of the cornea in vivo using a
normal or diseased rabbit model. New Zealand White rabbits, adeno-associated virus serotype 5 (AAV5), and a minimally
invasive hair-dryer based vector-delivery technique were used. Fifty microliters of AAV5 titer (6.561012 vg/ml) expressing
green fluorescent protein gene (GFP) was topically applied onto normal or diseased (fibrotic or neovascularized) rabbit
corneas for 2-minutes with a custom vector-delivery technique. Corneal fibrosis and neovascularization in rabbit eyes were
induced with photorefractive keratectomy using excimer laser and VEGF (630 ng) using micropocket assay, respectively. Slit-
lamp biomicroscopy and immunocytochemistry were used to confirm fibrosis and neovascularization in rabbit corneas. The
levels, location and duration of delivered-GFP gene expression in the rabbit stroma were measured with
immunocytochemistry and/or western blotting. Slot-blot measured delivered-GFP gene copy number. Confocal microscopy
performed in whole-mounts of cornea and thick corneal sections determined geometric and spatial localization of
delivered-GFP in three-dimensional arrangement. AAV5 toxicity and safety were evaluated with clinical eye exam,
stereomicroscopy, slit-lamp biomicroscopy, and H&E staining. A single 2-minute AAV5 topical application via custom
delivery-technique efficiently and selectively transduced keratocytes in the anterior stroma of normal and diseased rabbit
corneas as evident from immunocytochemistry and confocal microscopy. Transgene expression was first detected at day 3,
peaked at day 7, and was maintained up to 16 weeks (longest tested time point). Clinical and slit-lamp eye examination in
live rabbits and H&E staining did not reveal any significant changes between AAV5-treated and untreated control corneas.
These findings suggest that defined gene therapy approaches are safe for delivering genes into keratocytes in vivo and has
potential for treating corneal disorders in human patients.
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Introduction
The success of gene therapy to treat diseases in human patients
was first demonstrated over a decade ago [1]. Recent studies
reporting significant improvement in vision with gene therapy in
adult patients with Leber’s congenital amaurosis affirmed the
promise of gene therapy to treat eye diseases and prevent blindness
in humans [2,3]. In spite of the progress in gene therapy research,
many challenges including the severe side effects caused by the
vector and untargeted gene transfer remain to be resolved [4–6].
The success in the restoration of vision with gene therapy by
curing retinal disorders has encouraged more research for defining
gene therapy modalities for other ocular tissues. The potential of
gene therapy to treat corneal disease has been investigated using
various animal and in vitro models [7–13]. The cornea is an
attractive organ for gene therapy because of its accessibility,
immune-privileged status and ability to be monitored visually. The
three major cellular layers of the cornea are: epithelium, stroma
and endothelium. Gene therapy reagents can be administered into
epithelium and stroma topically, as well as into stroma and
endothelium with simple surgical procedures such as microinjec-
tion [13].
Major benefits of gene therapy are that it repairs the cause of
the problem and not merely suppress symptoms, provides long-
term cure, does not require repeated application or clinic visits.
Various viral and non-viral vectors have been tested to deliver
genes in the cornea [11–13]. Among viral vectors, adenoviruses
and retroviruses have been shown to deliver genes into the cornea
for short periods of time with moderate-to-severe inflammatory
responses [14–20]. However, both of these vectors are of limited
use for corneal gene therapy because of their inability to transduce
non-dividing cells, low transduction efficiency for corneal cells and
induction of immune reactions [12,13]. Adeno-associated virus
(AAV) and disabled lentivirus vectors offer better alternatives for
delivering genes into the corneal stroma and endothelium because
of their ability to transduce non-dividing cells [12,13]. Addition-
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ally, these vectors are non-pathogenic and typically drive long-
term transgene expression. AAV vectors are preferred over
lentivirus because of their superior safety profile and non-
pathogenicity to humans. More than 100 serotypes of AAV are
known but serotypes 1-9 have been extensively tested for gene
therapy [4,11–13,21]. AAV serotypes have shown a varied degree
of tissue selective tropism [21–27]. These reports led us to the
hypothesis that vector regulates amount of gene delivery in the
cornea. Indeed our recent studies supported our hypothesis as
AAV serotypes 2, 5, 6, 8, and 9 showed significantly different
transduction in the rodent and rabbit cornea in vitro and in vivo
[11,21,27,28]. Our studies also suggested that AAV serotypes 5, 8
and 9 are most efficient for transporting genes in the rodent and
rabbit stroma in vivo among various tested AAV serotypes
[11,21,27]. AAV5-treated rodent corneas continued to express
delivered transgene up to 1 year in vivo without any apparent side
effects (Mohan et al Unpublished data), and thus was selected for
this study.
The poor targeted delivery of therapeutic genes into corneal
cells in vivo is another major challenge that sharply limits clinical
application of gene therapy to treat corneal disorders and diseases.
Previously, we demonstrated that AAV and plasmid vectors could
deliver significant amount of genes into keratocytes of the rabbit
stroma in vivo if applied on bare stroma employing a lamellar flap
technique [28]. This led us to hypothesize that administration of
an efficient vector via a custom vector-delivery technique would
provide tissue-selective targeted transgene delivery in the cornea
with no major side effects. Thus, multiple minimally invasive
vector-delivery techniques to administer vector into keratocytes,
stroma or endothelium of the rabbit and rodent cornea in vivo were
optimized. Among many defined vector-delivery techniques, the
hair-dryer based technique manipulating corneal hydration, the
microinjection techniques using glass needle and Hamilton
microsyringes, the topical cloning cylinder based technique
employing 20% alcohol and the epithelial scrape technique using
#64 surgical blade have provided the most targeted gene delivery
into the targeted cells of the cornea in vivo [29]. The aim of this
study was to define site-selective tissue-targeted gene therapy
approaches using a suitable combination of efficacious AAV5
vector and newly-defined vector-delivery techniques to express
therapeutic genes selectively in keratocytes or the stroma of the
normal and damaged (fibrotic or neovascularized) rabbit cornea in
vivo.
Results
Characterization of AAV5-mediated gene transfer in
rabbit cornea
Figure 1 shows AAV5-mediated delivery of GFP gene in the
normal rabbit cornea detected using stereo- (Fig. 1A) and
fluorescent- (Fig. 1B–D) microscopy. Rabbits were subjected to
fluorescence imaging every 12 h for the first 3 days after AAV5
vector application, and thereafter once a week until euthanasia. All
rabbit corneas showed initial appearance of GFP gene expression
at day-3 (Fig. 1 C), which reached its maximum level at day-7.
Fig. 1D shows a representative image of peak level of GFP
expression in rabbit corneal tissue section detected at 2-week time
point. No fluorescence was detected in corneas of early tested time
points (12 h, 24 h, 48 h or 60 h). Rabbit corneas of later time
points (2-week, 4-week and 16-week) showed fluorescence levels
similar to the levels of 7-day time point. These observations
suggest that AAV5 delivered transgene expression first appeared
between 60 h to 72 h after vector application, continued to
increase for the next 4 days, peaked at day-7, and maintained high
transgene expression up to the longest tested time point of 16-week
(4 months) in the rabbit corneas in vivo.
Figure 1. Representative in vivo fluorescence stereomicrograph (A) and tissue sections (B–D) of rabbit corneas showing AAV5-
mediated GFP gene expression at 3-day and 2-week time points. Topical application of AAV5-GFP vector selectively transduced anterior
keratocytes (arrows) located beneath the epithelium (C, D). No transgene expression was detected in control corneas (A). The rabbit corneas collected
at 4-week and 16-week showed similar levels of GFP expression with immunostatining (data not shown). Nuclei are stained blue with DAPI. Scale bar
denotes 100 mm.
doi:10.1371/journal.pone.0018771.g001
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Quantification of AAV5-mediated gene transfer
The level of AAV5 delivered GFP gene expression was
quantified using western blot. Figure 2 shows the levels of
delivered GFP protein in rabbit corneas at various tested time
points (2-day, 3-day, 7-day, 2-week, 4-week and 16-week) after
single topical application of AAV5. The digital quantification of
the western blot depicting the average pixels of three independent
experiments is shown in Figure 2. The first detectable expression
was noted at day-3 (4099 pixels6682). The maximum GFP
expression was observed at day-7 (7100 pixels6154), which was
significantly higher compared to day-3 (p,0.05) and balanced salt
solution (BSS)-treated controls (p,0.01). Also, the GFP expression
detected at other tested time points of 2-weeks (7021 pixels6462),
4-weeks (6998 pixels6473) and 16 weeks (6880 pixels6698) was
significantly (p,0.05) higher than the GFP expression detected at
day-3 as well as BSS-treated controls. No GFP expression was
detected in BSS-treated control rabbit corneas. Equal loading of
protein was confirmed by the detection of similar intensity b-actin
bands.
Spatial localization of AAV5-mediated GFP gene transfer
To detect spatial localization of AAV5-mediated gene transfer
in the rabbit cornea, we performed confocal microscopy in rabbit
corneal tissues collected 3 days and 2 weeks after AAV5
application. The three-dimensional z-stack confocal images
presented in Figure 3 reveal localization of GFP in rabbit corneas
of 3-day (A) and 2-week (B) time points. As evident from this
figure, the delivered-GFP gene expression was detected in the
anterior stroma just below the corneal epithelium. No transgene
expression was detected either in the corneal epithelium or
posterior stroma or corneal endothelium. These observations
suggest that AAV5 vector administered to the rabbit cornea with
defined vector-delivery technique provided tissue-selective local-
ized gene delivery in the anterior stroma.
Determination of delivered-GFP gene copies with AAV5
To understand the correlation between delivered-GFP gene
copy number and expression of delivered-GFP protein, we
measured AAV5-delivered GFP gene copy number in rabbit
corneas using slot blot. Figure 4 shows the gene copy number
delivered in two separate rabbit corneas detected at 2-week time
point using slot blot method. Densitometric analysis revealed that
108–1010 genomic copies of transgene were detected in the rabbit
corneas. This data complement the results of immunocytochem-
istry (Fig. 1) and western blotting (Fig. 2).
AAV5-mediated gene delivery in diseased rabbit corneas
Diseases affecting the corneas are associated with significant
alterations in corneal homeostatic and/or cellular phenotype.
Thus, we raised a question ‘‘do gene transfer parameters
optimized using normal rabbit corneas are applicable for the
diseased cornea?’’ To answer this question we used two most
acceptable in vivo rabbit disease models; the PRK-based corneal
scarring model and the VEGF-induced corneal neovascularization
model to test the potential of optimized tissue-targeted gene
transfer approaches using AAV5 for treating corneal diseases such
as corneal fibrosis and corneal neovascularization. The gene
transfer data observed in scarred rabbit cornea is shown in
Figure 5. The detection of transdifferentiated keratocytes (myofi-
broblasts) with aSMA (a fibrosis biomarker) immunostaining
(Fig. 5A) shown in red confirmed the scarring in rabbit corneas
induced by PRK surgery. AAV5-delivered GFP gene expression
(shown in green color) detected at 3-day (Fig. 5B) and 2-week
(Fig. 5C) time points is shown in green. As evident from Figure 5B
and 5C, AAV5 delivered significant levels of GFP in the anterior
stroma of the scarred rabbit cornea. Furthermore, co-localization
of GFP and aSMA (detected in yellow) suggests that transgene was
also delivered into transdifferentiated keratocytes (myofibroblasts)
in addition to keratocytes by this technique. These observations
revealed that defined gene transfer parameters are efficient for
corneal gene therapy.
Next, we evaluated the efficiency of defined gene transfer
parameters using AAV5 for delivering genes into neovascularized
rabbit corneas. Figure 6 shows that a single 2 minutes topical
application of AAV5-GFP vector on the rabbit stroma delivered
significant levels of transgene into neovascularized rabbit corneas
further validated suitability of optimized parameters and tested
AAV5 vector for delivering therapeutic genes in diseased corneas.
The increased GFP expression detected at 7-day (Fig. 6C)
compared to 3-day (Fig. 6B) time point suggests that neovascu-
larization did not alter kinetics of AAV5-mediated gene transfer.
GFP delivery and blood vessel formation in the rabbit corneal
section in Figure 6 is shown with GFP immmunostaining with
green and lectin staining in red, respectively.
Safety determinations with slitlamp biomicroscopy and
histology of AAV5-treated rabbit corneas
To analyze the effects of AAV5 on corneal health, visual and
slit-lamp clinical examinations were performed in the eyes of live
rabbits 1-day, 2-day, 3-day, 7-day and 4-week after BSS or AAV5
application. Neither BSS (Fig. 7A) nor AAV5-GFP (Fig. 7B)
treated rabbit eyes showed inflammation, unusual discharge,
swelling, redness or infection in the eye during clinical
examination suggesting that AAV5 vector and used topical
delivery technique are safe for the rabbit cornea. The
hematoxylin and eosin-staining of BSS-treated control (Fig. 7C)
and AAV5-treated rabbit corneas (Fig. 7D) collected at various
time points did not exhibit any apparent structural abnormalities
or abnormal infiltration of inflammatory cells in the rabbit cornea
further confirming the safety of AAV5 vector for corneal gene
delivery.
Figure 2. Representative western blot (upper panel) and digital
quantification (lower panel) of delivered trangene in rabbit
corneas at various time points. The delivered transgene expression
first detected at 3-day, peaked at 7-day and maintained up to longest
tested 16-week time point. b-actin was used to confirm equal loading of
protein in each well and normalization of data. * p,0.05 compared to
BSS-treated controls and 3-day time point, and t p,0.01 compared to
BSS-treated control.
doi:10.1371/journal.pone.0018771.g002
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Discussion
Gene therapy offers a novel opportunity to cure ocular surface
disorders by targeting the underlying cause as opposed to simply
treating the symptoms with conventional drug treatment. Safe and
successful progression of gene therapy from bench-to-bedside
application requires delivery of therapeutic genes into targeted
tissue in a selective manner. The major reasons for the failure of
gene therapy are the severe side effects because of the uncontrolled
and untargeted delivery of therapeutic genes into tissues [5]. This
study, for the first time, demonstrates site-selective targeted gene
delivery into keratocytes of normal and damaged corneas in vivo
using a rabbit model, and reports optimal conditions for achieving
controlled and targeted expression of therapeutic genes in the
cornea for treating blindness due to corneal disorders. Further-
more, our data demonstrate that AAV5 is an efficacious and safe
vector for corneal gene therapy as a single two minute topical
application of vector provided high levels of delivered-gene
starting from day three and lasting over several months without
causing significant side effects.
Corneal epithelium spans 5–7 cell layers and acts as a barrier to
prevent entry of foreign particles and pathogens into the eye. We
previously found that removal of corneal epithelium is a critical
step for achieving high levels of transgene delivery in the stroma of
mouse and rabbit corneas in vivo [21,28,29]. The removal of
corneal epithelium via gentle scraping is a common clinical
practice in the ophthalmology clinic to treat corneal epithelial
defects, and its removal is a standard step in photorefractive
keratectomy and laser epithelial keratomileusis surgeries. The
healthy corneal epithelium regenerates within 24–72 hours after
removal without causing any detrimental effects to the eye. Thus,
to test our postulate that direct interaction of AAV to the bare
stroma would provide enhanced gene delivery into keratocytes we
took advantage of a common clinical practice of removing corneal
epithelium, and topically applied AAV5 on de-epitheliazed
corneas. Based on the lessons learned from our earlier studies
that epithelial injury could lead keratocyte apoptosis in the
anterior stroma and affect corneal healing, epithelial removal was
carried-out by gentle scarping by advancing the blade from a 45u
angle. This minor technique adjustment showed minimal
apoptosis and depletion in keratocyte density in anterior stroma
of the rabbit cornea. Topical application is the most acceptable
method for delivering therapeutics to the eye and was therefore
chosen for the study. However, topical dispensing not only renders
contact of therapeutics to the cornea but also to other ocular
tissues such as conjunctiva, sclera, iris, etc. To limit non-targeted
ocular tissue transduction and maximize transgene delivery into
Figure 3. Representative three-dimensional confocal microscopy images showing spatial localization of GFP-expressing
keratocytes (arrows) in whole-mount rabbit corneas exposed to AAV5. Corneas collected 3 days (A) and 2 weeks (B) after topical
application of AAV5-GFP vector showed GFP-positive keratocytes beneath the epithelium in the anterior stroma. Nuclei are stained blue with DAPI.
Scale bar denotes 75 mm.
doi:10.1371/journal.pone.0018771.g003
Figure 4. Slot blot showing GFP gene copy number in AAV5-
GFP treated rabbit corneas. Densitometric comparison detected
108–1010 copies of GFP gene in AAV5 GFP-treated rabbit corneas. Left
lane shows standard plot of GFP plasmid DNA copies blotted at 10-fold
dilution series. The right lane shows delivered GFP DNA copies detected
in rabbit corneas collected 2-week after AAV5-GFP application.
doi:10.1371/journal.pone.0018771.g004
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keratocytes, a custom-cloning cylinder was used [29]. It has been
our central hypothesis that localized and controlled administration
of vector in the cornea via minimally invasive simple surgical
techniques would allow targeted therapeutic gene delivery into
desired cells of the cornea, in vivo. We used this approach for
defining tissue-selective gene therapy approaches for the cornea
because it does not require usage of a cornea-tissue specific
promoter. At present, keratocan and the aldehyde dehydrogenase
3 cornea-specific promoter are generally used but both have their
own limitations including leaky expression [30–32].
Corneal stroma is affected in many clinical disorders including
corneal scarring, neovascularization, keratitis, graft rejection, ulcer
and genetic dystrophies. Keratocytes residing in the stroma play
an important role in maintaining corneal homeostasis, wound
healing and clarity [33,34]. Identification of efficacious and safe
gene therapy approaches for the stroma has potential to lead to the
development of novel therapeutic modalities for treating these
corneal diseases and disorders [8,12,13]. It is well documented that
during pathologic conditions keratocytes undergo phenotypic
changes. This raises a question whether gene therapy methods
optimized using normal corneas or healthy keratocytes could also
be applicable to diseased conditions. In this study we addressed
this issue by evaluating the efficiency of defined tissue targeted
gene therapy approaches using two well-established animal disease
models; rabbit corneal scarring and rabbit corneal neovascular-
ization. In scarred rabbit corneas, AAV5 efficiently delivered GFP
gene in the stroma and transduced a significant population of
keratocytes as well as other cell types such as myofibroblasts
whereas in neovascularized rabbit cornea transgene delivery was
detected predominantly in keratocytes. On one hand, these
findings confirmed that defined gene transfer approaches could
efficiently deliver therapeutic genes to diseased corneas; on the
other hand, the findings prompted us to raise another clinically
relevant and important question ‘‘what would be a more effective
therapeutic strategy: to deliver therapeutic gene into transdiffer-
entiated keratocytes or normal keratocytes?’’ We postulate that it
will largely depend on the selection of the therapeutic gene. For
example, corneal scarring treatment with basic fibroblast growth
factor (FGF2) gene would require targeted delivery of FGF2 gene
into myofibroblasts (transdifferentiated keratocytes) as Maltseva
et al. have shown transdifferentiation of myofibroblasts to
keratocytes by FGF2 in vitro [35]. There is a possibility that
FGF2 gene delivery into normal keratocytes could induce
neovascularization in the cornea. This assumption is based on
the fact that implantation of recombinant FGF2 pellet in the
stroma is used to induce angiogenesis in the cornea [36,37]. Our
future studies will address such important questions.
Preclinical studies testing gene delivery in cornea have used a
wide array of viral vectors. Multiple factors such as tissue tropism,
duration of gene expression, vector gene carrying capacity,
integrating or non-integrating nature of the vector, toxicity and
safety of vector etc. dictate the choice of vector for clinical
Figure 5. Representative images of corneal sections showing efficacy of AAV5-mediated transgene delivery in fibrotic rabbit
corneas. Corneal fibrosis was produced by PRK laser surgery which induces transdifferentiation of keratocytes (myofibroblasts showing red staining
for aSMA). Keratocytes expressing delivered GFP are shown in green (arrow), transdifferentiation keratocytes (myofibroblasts) expressing GFP and a-
smooth muscle actin are shown in yellow (arrowheads), and transdifferentiation keratocytes (myofibroblasts) expressing a-smooth muscle actin are
shown in red (Cut arrowheads). Nuclei are stained blue with DAPI. Scale bar denotes 100 mm.
doi:10.1371/journal.pone.0018771.g005
Figure 6. Representative in vivo images of corneal tissue sections showing efficacy of AAV5-mediated transgene delivery in
neovascularized rabbit cornea. Keratocytes expressing delivered GFP are shown in green (arrowheads). Blood vessels are stained red with lectin
(arrows). Nuclei are stained blue with DAPI. Scale bar denotes 100 mm.
doi:10.1371/journal.pone.0018771.g006
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application of gene therapy. The safety and toxicity of vector to
the patient and the environment remained a major determinant
that enabled AAV to emerge as a vector of choice among viral
vectors for ocular gene therapy. AAV is considered the safest viral
vector because of its low immunogenic properties and non-
pathogenicity to humans. The ocular gene therapy clinical trials
carried-out with AAV serotype 2 (AAV2) for the retina have not
reported any severe immune or inflammatory reactions among
patients with used AAV vectors [38–40]. Like AAV2, AAV5
employed in this study did not show any significant side effects
including the immune reaction or corneal damage suggesting that
selected AAV5 is safe for corneal gene therapy. Scores of studies
have demonstrated that AAV5 has superior transduction efficacy
than AAV2 for ocular and non-ocular tissues [8,38,41]. Another
factor that favors use of AAV5 for human gene therapy is the
presence of AAV2 neutralizing antibodies in humans, which
diminishes efficacy of AAV2 [42].
In summary, the site-selective controlled gene therapy ap-
proaches for the cornea defined using AAV5 vector and minimally
invasive simple surgical technique may be effectively applied
clinically to deliver genes in the eye to treat blindness from corneal
stromal abnormalities. The AAV5 may potentially be a preferred
vector for corneal gene therapy because of higher transduction
efficiency and safety profile compared to AAV2.
Materials and Methods
Animals
The Institutional Animal Care and Use Committee of the
University of Missouri-Columbia, Missouri USA USA (ID# 4279
and 6487) and Harry S. Truman Memorial Veterans’ Hospital
Columbia, Missouri USA (ID# 0041 and 0089) approved the
study. Animals were treated in adherence to the principles of the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. New Zealand White rabbits (Myrtle laboratories
Inc., Thompson’s Station, TN) weighing 2.5–3.0 kg were used in
this study. Rabbits were anesthetized by intramuscular injection of
ketamine hydrochloride (50 mg/kg) and xylazine hydrochloride
(10 mg/kg) for performing PRK, VEGF-implantation, stereo- and
slit-lamp biomicroscopy.
AAV5 vector generation
The AAV5 expressing green fluorescent protein gene (AAV5-
GFP) titer produced at the Gene Therapy Vector Core Lab,
University of Florida, Gainesville, Florida was procured from Prof.
Gregory S. Schultz and Dr. Vince A. Chido. Following an earlier
reported method the AAV2 plasmid pTRUF11 expressing
fluorescent green protein gene under control of a hybrid promoter
(cytomegalovirus enhancer and chicken b-actin) and simian virus
40 polyadenylation site was packaged into AAV5 [43]. In brief,
AAV5 vector was produced by the 2-plasmid, co-transfection
method. One Cell Stack (Corning Inc., Corning, NY, USA) with
approximately 16109 HEK 293 cells was cultured in Dulbecco’s
Modified Eagle’s Medium (Hyclone Laboratories, Inc. Logan UT,
USA), supplemented with 5% fetal bovine serum and antibiotics.
A CaPO4 transfection precipitation was set up by mixing a 1:1
molar ratio of AAV2 plasmid DNA containing GFP and AAV5
rep–cap helper plasmid DNA. This precipitate was applied to the
cell monolayer and the transfection was allowed to incubate at
37uC, 7% CO2 for 60 h. The cells were then harvested and lysed
by freeze/thaw cycles and subjected to discontinuous iodixanol
gradients centrifugation at 350,000 g for 1 h. This iodixanol
fraction was further purified and concentrated by column
chromatography on a 5-ml HiTrap Q Sepharose column using
a Pharmacia AKTA FPLC system (Amersham Biosciences,
Piscataway, NJ, USA). The vector was eluted from the column
Figure 7. Representative slit lamp microscopy and images demonstrating safety of tested AAV5 to the cornea. No inflammation,
redness, water discharge, swelling, etc was observed in BSS-treated control (A) or AAV5-treated corneas (B). Hematoxylin and eosin staining of
corneal tissue sections (D) obtained from AAV5-treated rabbit eyes showed corneal morphology comparable to control corneas (C). Panels A–D
shows data of 1-day time point. Similar observations were recorded for other tested time points (data not shown). Scale bar denotes 100 mm.
doi:10.1371/journal.pone.0018771.g007
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using 215 mM NaCl buffer, pH 8.0, and the rAAV peak collected.
AAV5 GFP vector-containing fraction was then concentrated and
buffer exchanged in Alcon BSS with 0.014% Tween 20, using a
Biomax 100 K concentrator (Millipore, Billerica, MA, USA).
Vector was titered for DNAse-resistant vector genomes by Real-
Time PCR relative to a standard.
AAV5 transduction to rabbit cornea
Twenty-eight rabbits ware used for the study. Only one eye of
each rabbit selected randomly was used for the experiment.
Sixteen rabbits were divided into two groups for the optimization
of gene delivery parameters for the cornea. Rabbits of AAV5-
treated group (n= 10) received 100 ml titer (6.561012 vg/ml) of
AAV5 expressing green fluorescent protein gene under control of
cytomegalovirus enhancer and chicken b-actin promoters topically
for 2 minutes on de-epithelialized cornea via a custom hairdryer
based vector delivery technique reported recently [29]. The
control group (n = 6) received balance salt solution (BSS) topically
using similar conditions. Twelve rabbits were used to evaluate the
efficiency of optimized gene transfer parameters for delivering
genes into diseased corneas namely rabbit corneal scarring model
(n = 6) and rabbit neovascularization model (n = 6) were used. The
AAV5 vector was topically applied to scarred rabbit cornea 4
weeks after PRK (n= 6) or neovascularized rabbit corneas 5-day
after VEGF implantation (n= 6) using similar vector volume, titer,
delivery technique, and experimental conditions. The contralat-
eral eyes served as a naive control.
Corneal neovascularization and haze generation
Neovascularization in rabbit cornea was induced by corneal
micro-pocket assay [44]. Rabbits were anesthetized with ketamine
and xylazine, and 3–4 drops of 0.5% topical proparacaine
hydrochloride solution (Alcon, Ft. Worth, TX, USA) was applied
to the eye prior to cornea micropocket surgery. Only one eye of
each animal was used for surgical procedure. The contralateral eye
served as naive control. A wire speculum was positioned in the eye
and a sucralfate-hydron pellet containing 650 ng of VEGF
(PeproTech, Rocky Hill, NJ) was implanted into the cornea after
making a micropocket in the cornea using standard surgical tools.
Triple antibiotic ointment (Alcon) was applied to the surface of the
cornea after pellet implantation to prevent infection. The ingrowth
of blood vessels in the cornea towards the VEGF implant started
from day 2, peaked around day 10 and continued to grow
progressively up to 15 days before regressing.
Haze in rabbit cornea was produced by performing photo-
refractive keratectomy (PRK) surgery in an anaesthetized rabbit
[45]. Topical proparacaine hydrochloride 0.5% (Alcon, Ft. Worth,
TX, USA) was applied to each eye just before PRK. A wire lid
speculum was positioned and a 7 mm-diameter area of epithelium
overlying the pupil was removed by scraping with a #64 blade
(Beaver; Becton-Dickinson, Franklin Lake, NJ, USA). The 29.0
diopter PRK surgery with a 6 mm ablation zone on the central
stroma was performed using the Summit Apex excimer laser
(Alcon, Ft. Worth, TX). Only one eye from each animal was used
for PRK and the contralateral eye served as naive control. The
corneal haze in animals peaked 4 weeks after PRK.
Clinical and slit-lamp biomicroscopy
The health of the cornea in eyes of live rabbits was examined by
visual clinical and slit-lamp microscopic (BX 900 Slit Lamp, Haag-
Streit-USA, Mason OH) examinations before and after AAV5
application in normal and diseased (hazy or neovascularized)
rabbit corneas by two ophthalmologists and a researcher,
independently and in a blinded manner while animals were under
general anesthesia. Thereafter, corneal health was monitored
every third day with a hand-held slit-lamp microscope (SL-15,
Kowa Optimed Inc., Torrance, CA). Photographs of the cornea
were taken with a digital camera attached to the BX 900 slit-lamp
microscope.
Tissue collection
Rabbits were humanely euthanized with pentobarbitone
(150 mg/kg) overdose under general anesthesia at selected time
points. Rabbit corneas were removed with forceps and sharp
Westcott scissors and cut into 2 equal halves. One half was
embedded in liquid optimal cutting temperature (OCT) compound
(Sakura FineTek, Torrance, CA) within a 24 mm624 mm65 mm
mold (Fisher, Pittsburgh, PA) and snap frozen. Frozen tissue blocks
were maintained at 280uC. Tissue sections were cut 7 mm thick
with a cryostat (HM 525 M, Microm GmbH, Walldorf, Germany).
Sections were placed on 25 mm675 mm61 mm microscope
Superfrost Plus slides (Fisher), and maintained frozen at 280uC
until staining. The other half of rabbit corneal tissues was snap
frozen directly in liquid nitrogen for isolating RNA, DNA or
protein.
Immunohistochemistry and hematoxylin and eosin
staining
Corneal tissues were stained with hematoxylin and eosin (H &
E). Immunofluorescence staining for alpha smooth muscle actin
(aSMA), a marker for myofibroblasts, was performed using mouse
monoclonal primary aSMA antibody (1:200 dilution, catalog
no. M0851, Dako, Carpinteria, CA). Tissue sections were
incubated with 2% bovine serum albumin for 30 minutes at room
temperature and then with aSMA monoclonal antibody for
90 minutes. For the detection of the primary antibody, Alexa 488
goat anti-mouse IgG secondary antibody (1:1000 dilution; catalog
no. A11001, Invitrogen Inc., Carlsbad, CA) for 1 hour was used.
Blood vessel formation was confirmed with tomato lectin
staining which entailed the incubation of corneal sections with
20 mg/ml Texas red-conjugated tomato lectin (cat # TL-1176;
Vector laboratories, Burlingame, CA) for 90 min. Tissue sections
were washed in HEPES buffer and mounted using Vectashield
medium containing 49-6-diamidino-2-phenylindole (DAPI; Vector
laboratories). The stained sections were viewed and photographed
with a Leica fluorescent microscope (Leica DM 4000B; Leica)
equipped with a digital camera (SpotCam RT KE).
Immunoblotting
Protein lysates were prepared by homogenizing corneas in
protein lysis buffer containing protease inhibitor cocktail (Roche
Applied Sciences, Indianapolis, IN). Total protein was determined
with Bradford assay. The same amount of protein of each sample
was suspended in Laemmli denaturing sample buffer, vortexed
and heated for 10 min at 70uC. The proteins were resolved on 4–
20% SDS-PAGE gel and transferred onto 0.45 mm pore size
PVDF membrane (Invitrogen, San Diego, CA). The membrane
was incubated with GFP (cat # sc-33856; Santa Cruz) or b-actin
(cat # sc-69879; Santa Cruz) primary antibody followed by
alkaline phosphatase-conjugated anti-goat or anti-mouse second-
ary antibody (Santa Cruz). The bands were visualized by NBT/
BCIP.
Stereo-biomicroscopy and confocal microscopy
Fluorescent stereomicroscope (model MZ16F, Leica) was used
to track GFP expression in the eye of live rabbits under general
anesthesia. The spatial localization of delivered-GFP gene in
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whole-mounts of normal cornea and thick tissue sections of
damaged corneas was determined with confocal microscope (TCS-
SP; Leica or Radiance 2000; Bio-Rad) using corresponding lasers
for DAPI and GFP. The paraformaldehyde (4%) fixed corneal
whole-mount tissues were stained with DAPI for 3 days to stain
nuclei. The 20 mm thick corneal sections of the damaged rabbit
corneas were subjected to triple staining (nuclei with DAPI in blue,
cells expressing-GFP in green, and cells expressing SMA or lectin
with red). The Z-stacks were generated in 0.45 mm increments and
3-D reconstructions were created by computer using Velocity
software (Impro Vision Inc., Lexington, MA). The 3-D images
were rotated 360u for spatial and perceptual visualization of the
corneal regions. The exact location and quantity of the EGFP-
positive cells in the cornea were measured with Velocity software
(Impro Vision) and NIH Image J software.
Slot blot analysis
The copies of delivered plasmid were determined with slot blot
analysis. Frozen corneal tissues were ground in liquid nitrogen and
DNA was isolated using the DNA easy kit (Qiagen, cat # 69504).
The standards were prepared using 104–1011 copies of decorin
gene cloned into pTRUF11 vector. The DNA probe was prepared
by digesting 5 mg of decorin plasmid with Not1 restriction enzyme
and labeling 1 mg of isolated decorin fragment with digoxigenin
(DIG)-labeled UTP, using DIG starter Kit II (catalog
no. 11585614910 Roche Applied Science, Indianapolis, IN).
Two microliters of the standard as well as the DNA isolated from
corneal tissues was denatured by alkali and heat treatment.
Denatured DNA samples were blotted onto nylon membrane
using slot blot apparatus (BioRad lab) and were UV-cross linked.
The membrane was hybridized with 300 ng of digoxigenin (DIG)-
labeled probe overnight at 30uC, followed by incubation in 1:5000
anti-digoxigenin-AP antibody. Chemiluminiscent detection was
used following vendor’s instructions (catalog no. 11585614910
Roche Applied Science, Indianapolis, IN) and membrane was
exposed to X-ray film. Image J 1.386 image analysis software was
used to determine delivered gene copies in samples by measuring
dot intensities of samples and comparing the data with standards.
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